RT Journal Article
SR Electronic
T1 GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.17.20133579
DO 10.1101/2020.06.17.20133579
A1 Corral-Gudino, Luis
A1 Bahamonde, Alberto
A1 Arnaiz-Revillas, Francisco
A1 Gómez-Barquero, Julia
A1 Abadía-Otero, Jesica
A1 García-Ibarbia, Carmen
A1 Mora, Víctor
A1 Cerezo-Hernández, Ana
A1 Hernández, José L.
A1 López-Muñíz, Graciela
A1 Hernández-Blanco, Fernando
A1 Cifrián, Jose M.
A1 Olmos, Jose M.
A1 Carrascosa, Miguel
A1 Nieto, Luis
A1 Fariñas, María Carmen
A1 Riancho, José A.
A1 ,
A1 Bahamonde, Alberto
A1 Hernández-Blanco, Fernando
A1 Buelta-González, Cristina
A1 Marcos-Martínez, Luis A.
A1 Martínez-Vidal, Ana I.
A1 Dosantos-Gallego, Pilar R.l
A1 Pérez-Sagredo, Jesús
A1 Sandomingo-Freire, Silvia
A1 Muñumer-Blázquez, Rebeca
A1 Paredes-Mogollo, Antonio
A1 Brague-Allegue, Elena
A1 Carrascosa, Miguel
A1 García-Rivero, Juan L.
A1 Riancho, José A.
A1 Olmos, José M.
A1 Fariñas, Carmen
A1 Cifrian, José M.
A1 García-Ibarbia, Carmen
A1 Hernández, Jose L.
A1 Arnaiz-Revillas, Francisco
A1 Mora, Victor
A1 Nieto, Sara
A1 Ruiz-Cubillán, Juan
A1 Bermúdez, Arancha
A1 Pardo, Javier
A1 Amado, Carlos
A1 Insunza, Andrés
A1 Gil, Aritz
A1 Diaz-Terán, Teresa
A1 Fayos, Marina
A1 Zabaleta, Miguel A.
A1 Parra, Juan J.
A1 Corral-Gudino, Luis
A1 Gómez-Barquero, Julia
A1 Abadía-Otero, Jesica
A1 Cerezo-Hernández, Ana
A1 López-Muñíz, Graciela
A1 Ruíz-de-Temiño-de-la-Peña, Angela
A1 Arroyo-Domingo, C. Ainhoa
A1 Mena-Martín, Javier
A1 Miramontes-González, Pablo
A1 Jiménez-Masa, Ana E
A1 Pastor-Mancisidor, Luis
A1 Álvaro-de-Castro, Tanía M
A1 Pérez-Panizo, María Cruz
A1 Ruíz-Albi, Tomás
A1 de-la-Colina-Rojo, C Gema
A1 Andrés-Calvo, María
A1 Crespo-Sedano, Andrea
A1 Morejón-Huerta, Begoña
A1 Briongos-Figuero, Laisa S.
A1 Frutos-Arriba, Julio F
A1 Pagán-Buzo, Javier
A1 Gabella-Martín, Miriam
A1 Cobos-Siles, Marta
A1 Gómez-García, Ana
A1 Nieto, Luis
YR 2020
UL http://medrxiv.org/content/early/2020/06/18/2020.06.17.20133579.abstract
AB Background We aimed to determine whether a 6-day course of intravenous methylprednisolone (MP) improves outcome in patients with SARS CoV-2 infection at risk of developing Acute Respiratory Distress Syndrome (ARDS).Methods Multicentric, partially randomized, preference, open-label trial, including adults with COVID-19 pneumonia, impaired gas exchange and biochemical evidence of hyper-inflammation. Patients were assigned to standard of care (SOC), or SOC plus intravenous MP [40mg/12h 3 days, then 20mg/12h 3 days]. The primary endpoint was a composite of death, admission to the intensive care unit (ICU) or requirement of non-invasive ventilation (NIV).Results We analyzed 85 patients (34, randomized to MP; 22, assigned to MP by clinician’s preference; 29, control group). Patients’ age (mean 68±12 yr) was related to outcome. The use of MP was associated with a reduced risk of the composite endpoint in the intention-to-treat, age-stratified analysis (combined risk ratio -RR-0.55 [95% CI 0.33-0.91]; p=0.024). In the per-protocol analysis, RR was 0.11 (0.01-0.83) in patients aged 72 yr or less, 0.61 (0.32-1.17) in those over 72 yr, and 0.37 (0.19-0.74, p=0.0037) in the whole group after age-adjustment by stratification. The decrease in C-reactive protein levels was more pronounced in the MP group (p=0.0003). Hyperglycemia was more frequent in the MP group.Conclusions A short course of MP had a beneficial effect on the clinical outcome of severe COVID-19 pneumonia, decreasing the risk of the composite end point of admission to ICU, NIV or death.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudraCT number: 2020-001934-37Funding StatementNo specific fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Etica en Investigacion con Medicamentos de CantabriaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequest from authors